Drugs Containing Excipient (Inactive Ingredient) CALCIUM CHLORIDE

« Back to Dashboard

Branded drugs containing CALCIUM CHLORIDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ALPHAGAN P	brimonidine tartrate	0023-9321	CALCIUM CHLORIDE
Alcon Laboratories Inc	MIOSTAT	carbachol	0065-0023	CALCIUM CHLORIDE
Alcon Laboratories Inc	TRIESENCE	triamcinolone acetonide	0065-0543	CALCIUM CHLORIDE
Novartis Pharmaceuticals Corporation	TOBI PODHALER	tobramycin	0078-0630	CALCIUM CHLORIDE
Novartis Pharmaceuticals Corporation	TRIESENCE	triamcinolone acetonide	0078-0897	CALCIUM CHLORIDE

Generic drugs containing CALCIUM CHLORIDE excipient

Company	Ingredient	NDC	Excipient
Allergan Inc	brimonidine tartrate	0023-9321	CALCIUM CHLORIDE
Alcon Laboratories Inc	carbachol	0065-0023	CALCIUM CHLORIDE
Alcon Laboratories Inc	triamcinolone acetonide	0065-0543	CALCIUM CHLORIDE
Pfizer Laboratories Div Pfizer Inc	epoetin alfa-epbx	0069-1305	CALCIUM CHLORIDE
Novartis Pharmaceuticals Corporation	tobramycin	0078-0630	CALCIUM CHLORIDE

Calcium Chloride Excipient Market Dynamics and Financial Trajectory

Last updated: October 12, 2026

Calcium chloride is a low-cost, high-volume inorganic salt with a small pharmaceutical-grade segment. Its pharmaceutical role is often misunderstood: calcium chloride is primarily an active pharmaceutical ingredient in injectable electrolyte products, while excipient demand arises in formulation processing, hardening, stabilization, and selected oral or topical applications. The commercial market is driven more by industrial, food, deicing, water-treatment, and oilfield demand than by pharmaceutical consumption.

The near-term financial outlook is stable to moderately positive. Volume growth should track injectable-drug production, biologics manufacturing, food processing, and regional healthcare investment. Margin performance will remain more sensitive to energy, hydrochloric acid availability, brine supply, freight, and grade qualification than to pharmaceutical pricing power.

What is calcium chloride used for in pharmaceutical manufacturing?

Calcium chloride is used in pharmaceutical products in several distinct ways:

Use	Commercial role	Typical form
Electrolyte replacement	Active ingredient for hypocalcemia and related emergencies	Sterile injectable solution
Manufacturing aid	Calcium source, ionic-strength modifier, or precipitation aid	Anhydrous or dihydrate powder
Cell and tissue processing	Calcium supplementation in media and process solutions	Pharmaceutical or biotechnology grade
Topical and oral products	Hardening, mineral supplementation, or formulation support	Solution, powder, or granules
Bioprocessing	Process reagent in selected upstream and downstream operations	High-purity solution or solid

Calcium chloride is available as anhydrous calcium chloride, CAS 10043-52-4, and calcium chloride dihydrate, CAS 10035-04-8. The selected form affects assay, water content, stability, handling, and the quantity required in a formulation.

In injectable medicines, calcium chloride is generally the active ingredient rather than an inactive excipient. FDA labeling identifies calcium chloride injection as a calcium-replacement product used for acute hypocalcemia and other emergency indications.[1]

How large is the calcium chloride pharmaceutical-grade market?

Public market reports usually combine pharmaceutical calcium chloride with food, industrial, deicing, water-treatment, construction, and oilfield grades. Reported global market estimates for all-grade calcium chloride generally fall in the low-single-digit billions of dollars, with forecast growth in the mid-single digits. The pharmaceutical-grade segment is a small portion of total volume but has higher unit pricing and qualification value.

Market layer	Demand profile	Pricing characteristics
Industrial and deicing	Largest volume segment	Commodity pricing
Food grade	Large, recurring demand	Moderate premium
Pharmaceutical grade	Small volume, specification-driven	High price per kilogram
Sterile injectable product	Finished-dose market	Highest value per kilogram of calcium chloride

A useful financial distinction is between calcium chloride sales and calcium chloride-containing drug sales. The former is a chemical-materials business. The latter is a regulated pharmaceutical business in which the calcium chloride input is usually a small percentage of finished-product revenue.

No major public pharmaceutical company separately reports revenue from calcium chloride as an excipient. Supplier financial statements generally aggregate calcium chloride within broader chemical, specialty-material, laboratory, or pharmaceutical-ingredient revenue.

What is driving calcium chloride excipient demand?

Injectable drug manufacturing

Demand for calcium chloride injection is tied to hospital utilization, emergency medicine, intensive care, electrolyte replacement, and generic injectable manufacturing. Growth is usually steady rather than rapid because the molecule is old, clinically established, and exposed to generic competition.

Shortages can create temporary price increases. Injectable calcium chloride requires sterile manufacturing, validated container-closure systems, endotoxin control, and regulatory compliance. These requirements create more value at the finished-product level than at the raw-material level.

Biopharmaceutical processing

Calcium ions are used in selected cell-culture, protein-processing, viral-vector, tissue-engineering, and laboratory workflows. This channel can support higher-purity demand, but it is application-specific. It does not convert calcium chloride into a major biopharmaceutical excipient category comparable with buffers, amino acids, polysorbates, or sugars.

Food and nutrition applications

Food processing provides a larger and more predictable specialty-grade market than pharmaceutical excipient use. Calcium chloride is used as a firming agent, electrolyte, processing aid, and mineral source. U.S. regulations list calcium chloride as a direct food substance permitted for specified uses under 21 C.F.R. § 184.1193.[2]

Food-grade demand can support manufacturing economics by increasing plant utilization, while pharmaceutical-grade production depends on documentation, contamination controls, and customer qualification.

Regional healthcare expansion

Growth in injectable manufacturing capacity in India, China, Southeast Asia, Latin America, and the Middle East should support demand for pharmaceutical-grade calcium chloride. Regional suppliers can compete on price, while North American and European buyers often place greater weight on audit history, pharmacopeial compliance, traceability, and continuity of supply.

What is the financial trajectory for calcium chloride suppliers?

The financial trajectory is best modeled as a mixed chemical-market exposure rather than a pure pharmaceutical-growth story.

Period	Expected market condition	Financial effect
2022-2023	Elevated logistics, energy, and chemical-input volatility	Higher realized prices but uneven margins
2024-2025	More normalized freight and input costs	Volume growth with margin normalization
2026-2028	Moderate demand growth across food, water treatment, and pharmaceuticals	Stable expansion; pricing remains cyclical
Downside case	Industrial slowdown, excess capacity, lower hydrochloric acid values	Price compression and weaker utilization
Upside case	Pharmaceutical shortages, stronger bioprocessing, tighter regional supply	Higher specialty-grade premiums

Calcium chloride is frequently produced from hydrochloric acid and calcium-containing feedstocks, or recovered as a byproduct of chemical processes. This creates a cost structure different from a conventional pharmaceutical active ingredient. Feedstock availability, plant utilization, purification requirements, packaging, and transportation can matter more than research and development spending.

OxyChem identifies calcium chloride among its chlor-alkali-related products and markets it into industrial and specialty applications.[3] TETRA Technologies also reports calcium chloride production and sales exposure through its completion-fluids and industrial businesses.[4] These disclosures show why financial results are usually linked to broader chemical and energy markets rather than to pharmaceutical demand alone.

Which companies supply pharmaceutical-grade calcium chloride?

The supply chain has four layers:

1. Large integrated chemical producers.
2. Specialty chemical manufacturers.
3. Pharmaceutical-ingredient distributors and repackagers.
4. Sterile injectable drug manufacturers.

Representative market participants include OxyChem and TETRA Technologies in large-scale calcium chloride production, along with specialty distributors such as Avantor, Merck, and Spectrum Chemical. Regional producers in India and China also supply pharmaceutical and laboratory grades.

Supplier selection normally depends on:

• USP, Ph. Eur., or equivalent compliance.
• Assay and impurity profile.
• Heavy-metal and elemental-impurity controls.
• Water content and particle-size control.
• Microbial and endotoxin specifications where applicable.
• Change-control procedures.
• Audit history and batch traceability.
• Dual-sourcing and geographic continuity.

Large chemical producers have cost advantages. Specialty suppliers can charge more when they provide small-pack formats, lot-specific documentation, regulatory support, and validated supply to pharmaceutical customers.

What regulatory status applies to calcium chloride?

Calcium chloride has no single global regulatory status. Requirements depend on whether it is sold as a drug substance, excipient, processing aid, laboratory reagent, food ingredient, or industrial chemical.

United States

FDA recognizes calcium chloride in approved drug products, including injectable products. The FDA Inactive Ingredient Database is relevant when calcium chloride is used as an inactive component in a particular dosage form and route.[5] The database does not establish unrestricted approval for every concentration, route, or formulation.

For finished injectable products, manufacturers must comply with current good manufacturing practice requirements, sterile-processing controls, container-closure validation, and applicable drug-application requirements.

Pharmacopeial status

Pharmaceutical buyers generally specify compliance with USP-NF, European Pharmacopoeia, British Pharmacopoeia, or another recognized standard. Pharmacopeial compliance does not eliminate the need for supplier qualification. A buyer may impose tighter limits than the monograph for aluminum, iron, magnesium, heavy metals, endotoxin, bioburden, or other impurities.

European Union and other markets

European buyers may require Ph. Eur. compliance, REACH documentation, GMP evidence, and excipient risk assessment under European pharmaceutical rules. China, Japan, India, and other regulated markets apply local pharmacopeial and registration requirements.

What patents protect calcium chloride formulations?

The calcium chloride molecule itself is not a meaningful patent-protection opportunity. It is an old, simple inorganic compound with extensive prior use. Core composition-of-matter patents are not commercially relevant.

Potential protection can arise from:

• A novel sterile injectable formulation.
• A particular concentration or pH range.
• A controlled-release dosage form.
• A calcium chloride combination product.
• A container-closure or delivery system.
• A manufacturing process that produces a defined impurity profile.
• A method of treating a narrowly defined patient population.

These rights would protect a product or use, not calcium chloride as a commodity excipient. The practical patent estate is therefore weak at the raw-material level and potentially stronger at the finished-drug or delivery-system level.

What is the Orange Book status of calcium chloride?

Calcium chloride products are generally exposed to the same generic-drug dynamics as other legacy injectable medicines. The principal commercial barrier is manufacturing and regulatory execution, not composition-of-matter exclusivity.

Issue	Assessment
Core molecule patent	No meaningful active patent barrier
Orange Book patent protection	Usually limited or absent for legacy calcium chloride injection products
New drug exclusivity	Generally not relevant to the established molecule
Generic competition	High where injectable manufacturing capacity exists
Regulatory barrier	Moderate to high for sterile injectable products
Raw-material barrier	Low to moderate, depending on grade and qualification

Orange Book patent listings apply to patents associated with approved drug products, not to the underlying chemical as a general commodity. A formulation patent or device patent could be listed if it satisfies FDA requirements, but such protection would be product-specific.[6]

Are Paragraph IV challenges relevant to calcium chloride?

Paragraph IV litigation is unlikely to be a central market issue for commodity calcium chloride or basic calcium chloride injection. A generic applicant could file an abbreviated new drug application with a Paragraph IV certification if an applicable listed patent existed. In practice, the more important barriers are:

• Sterile manufacturing capacity.
• FDA inspection readiness.
• Demonstration of equivalence.
• Container and closure performance.
• Supply continuity.
• Hospital contracting.
• Drug-shortage risk.
• Quality history.

For a simple injectable, a challenger can potentially enter after resolving regulatory requirements without confronting a durable composition patent. Any litigation would more likely involve a specific formulation, manufacturing method, delivery system, or combination product.

What formulation patents protect calcium chloride products?

Formulation protection is most plausible where the product solves a technical problem. Examples include:

• Reduced precipitation with other electrolytes.
• Improved stability in flexible infusion bags.
• Lower particulate formation.
• Extended shelf life.
• Compatibility with automated emergency-injection devices.
• Controlled release in oral or implantable dosage forms.
• Combination formulations with other calcium or electrolyte agents.

The commercial value of such patents depends on whether the feature is required by customers or merely preferred. A stability improvement that enables room-temperature storage can have more value than a narrow concentration claim if it reduces cold-chain cost or improves hospital inventory management.

What manufacturing and intellectual-property barriers exist?

The raw material has low intellectual-property barriers but meaningful operational barriers.

Manufacturing barriers

High-quality pharmaceutical calcium chloride production requires:

• Controlled feedstock quality.
• Removal of metals and insoluble material.
• Moisture control.
• Consistent particle size or solution concentration.
• Packaging that prevents contamination and moisture uptake.
• Validated cleaning and batch-release procedures.
• Supply-chain documentation.

Sterile calcium chloride injection adds aseptic processing, terminal sterilization considerations where applicable, endotoxin control, and container-closure testing.

Intellectual-property barriers

The strongest protectable positions are likely to be downstream:

• Novel dosage forms.
• Proprietary infusion systems.
• Combination products.
• Manufacturing processes with measurable quality advantages.
• Hospital-use devices.
• Specialized bioprocess formulations.

A supplier selling standard pharmaceutical-grade calcium chloride has limited ability to prevent substitution once an equivalent material is qualified.

What litigation and licensing activity affects calcium chloride?

There is no broad, high-value patent litigation pattern associated with commodity calcium chloride. Licensing is more likely to involve:

• Contract manufacturing.
• Regional distribution.
• Pharmaceutical-grade supply agreements.
• Sterile-fill arrangements.
• Technology transfer for injectable products.
• Dual-source qualification.

The absence of major licensing premiums at the molecule level reflects the mature status of calcium chloride. Commercial negotiations focus on price, minimum order quantities, quality agreements, change notification, lead times, and supply guarantees.

How does calcium chloride compare with competing calcium salts?

Product	Main advantage	Main limitation	Typical commercial position
Calcium chloride	High calcium content and rapid dissociation	Irritating intravenously; compatibility concerns	Emergency injectable and industrial
Calcium gluconate	Better tolerability in many clinical settings	Lower elemental calcium concentration	Common hospital calcium replacement
Calcium lactate	Oral and food applications	Less suitable for emergency injection	Nutrition and oral products
Calcium carbonate	Low cost and high calcium content	Poor water solubility	Supplements and antacids
Calcium citrate	Better absorption in selected settings	Higher cost	Nutritional supplements

Calcium chloride competes clinically with calcium gluconate more than it competes with other calcium salts in pharmaceutical manufacturing. Its value comes from rapid calcium delivery and high elemental-calcium content, while tolerability and administration risk limit use in some settings.

What generic launch scenarios exist?

Scenario 1: Commodity injectable entry

A new generic manufacturer enters with a standard calcium chloride injection. Pricing falls, but hospital demand remains stable. The entrant must secure reliable sterile capacity and compete for group-purchasing contracts.

Scenario 2: Supply-constrained entry

A manufacturer enters during a shortage or discontinuation. The product achieves temporary pricing power and gains hospital adoption, but margins normalize when incumbent supply returns.

Scenario 3: Premium formulation entry

A supplier develops a more stable or compatible formulation. The product may support higher pricing if it reduces administration risk, waste, or inventory complexity. Patent protection could apply, but the market remains limited by the size of the clinical need.

Scenario 4: Raw-material substitution

A finished-dose manufacturer qualifies a second calcium chloride supplier. The incumbent loses volume unless it maintains quality, price, and supply advantages. This is the most common competitive risk for excipient suppliers.

What geographic markets offer the strongest growth?

China and India offer the strongest manufacturing and volume-growth potential because of large chemical sectors, expanding pharmaceutical production, and growing export capacity. North America remains important for high-specification materials and injectable drug supply. Europe is attractive for regulated specialty supply but has higher compliance and energy costs.

Region	Opportunity	Risk
North America	Specialty and injectable supply	Mature demand and customer concentration
Europe	Pharmacopeial and high-purity products	Energy cost and regulatory burden
China	Scale and low-cost production	Qualification and geopolitical concerns
India	Generic injectable and API ecosystem	Capacity variability and documentation quality
Latin America	Healthcare and food-processing growth	Import dependence and currency exposure
Middle East	Water treatment and industrial demand	Lower pharmaceutical-grade scale

Key Takeaways

• Calcium chloride is mainly an industrial and food chemical; pharmaceutical excipient demand is a small, higher-value niche.
• In many pharmaceutical products, calcium chloride is the active ingredient rather than an excipient.
• The molecule has no meaningful composition-of-matter patent barrier.
• Finished injectable products can still face regulatory, manufacturing, formulation, and device-related barriers.
• Orange Book and Paragraph IV issues are generally secondary to sterile manufacturing and supply qualification.
• Financial performance depends on feedstock, energy, freight, plant utilization, and industrial demand.
• Pharmaceutical-grade suppliers gain pricing power through documentation, impurity control, validated processes, and supply continuity.
• Calcium chloride competes clinically most directly with calcium gluconate.
• The strongest growth opportunities are in regulated injectable supply, bioprocessing, and regional pharmaceutical manufacturing.
• Public companies do not generally disclose calcium chloride excipient revenue as a separate reporting segment.

FAQs

Is calcium chloride a pharmaceutical excipient or an active ingredient?

It can be either. In calcium chloride injection, it is generally the active ingredient. In selected formulations and manufacturing processes, it can function as an excipient, processing aid, hardening agent, or calcium source.

Does calcium chloride require an excipient master file?

A master-file strategy depends on the supplier, customer, jurisdiction, and intended use. Pharmaceutical buyers may accept a supplier qualification package, certificate of analysis, quality agreement, and regulatory documentation without requiring a formal master file.

Which calcium chloride grade is used in injectable drugs?

Injectable products require a qualified pharmaceutical or compendial grade with controlled impurities and validated sterile processing. Industrial or deicing grades are not interchangeable with injectable material.

Can calcium chloride suppliers obtain patent protection?

Suppliers generally cannot obtain meaningful patent protection over calcium chloride itself. Protection may apply to novel formulations, manufacturing processes, delivery devices, or combination products.

What is the largest commercial risk for pharmaceutical calcium chloride suppliers?

The largest risk is usually customer substitution or loss of qualification rather than patent expiry. A buyer can qualify a second source when the material is chemically equivalent and the supplier meets the required quality standard.

References

1. U.S. National Library of Medicine. (2024). DailyMed: Calcium chloride injection, USP. https://dailymed.nlm.nih.gov/
2. U.S. Food and Drug Administration. (2024). 21 C.F.R. § 184.1193: Calcium chloride. https://www.ecfr.gov/
3. Occidental Petroleum Corporation. (2024). 2023 annual report. https://www.oxy.com/
4. TETRA Technologies, Inc. (2024). 2023 annual report. https://ir.tetratec.com/
5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdIndex.cfm?event=basicSearch.page
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book